Intracorporeally injectable composition for implanting highly concentrated cross-linked atelocollagen
AssigneeKoken Co., Ltd.
InventorsTeruo Miyata, Tadatomo Kawai
Life of this patent
Estimating the term…
Abstract
The present invention provides an intracorporeally injectable non-toxic composition of atelocollagen having an excellent, long-lasting skin swelling effect due to its low viscosity, good fluidity, easy injectability and low antigenicity (without calcification) properties. The composition is prepared by treating an aqueous suspension of atelocollagen with a buffer for physiological conditions. The suspension can have atelocollagen content of 55 to 75 mg/ml, where approximately 20 to 100% by weight of atelocollagen is cross-linked with a polyepoxy compound.
Claims6
A composition comprising an aqueous suspension of atelocollagen adjusted for physiological conditions by a buffer to a concentration of 55 to 75 mg/ml of said atelocollagen, wherein said atelocollagen is cross-linked with a polyepoxy compound in an amount of 20 to 100% by weight and not less than 10% of amino side chain groups of atelocollagen contained in said cross-linked atelocollagen are cross-linked with said polyepoxy compound, said polyepoxy compound is a member selected from the group consisting of glycerol diglycidyl ether, glycerol triglycidyl ether, diglycerol tetraglycidyl ether, triglycerol pentaglycidy ether, poly (methylene glycol) diglycidyl ether (1-10 polymerization degree), poly (ethylene glycol) diglycidyl ether (1-10 polymerization degree), poly (trimethylene glycol) diglycidyl ether (1-8 polymerization degree) and poly (propylene glycol) diglycidyl ether (1-8 polymerization degree), said cross-linked atelocollagen has a transition point of not less than 40.degree. C. as measured by a differential scanning calorimeter, and said composition has a viscosity sufficient for injection through a needle.
Dependencies are inferred from the claim text.